Catalog No.
PMD71902
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse KLRC1 (Glu114-Ile227).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A
Purification
Purified by antigen affinity column.
Accession
Q9WU32
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma., PMID:40073259
CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors., PMID:39958331
Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862
Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy., PMID:39486805
NKG2C and NKG2A coexpression defines a highly functional antiviral NK population in spontaneous HIV control., PMID:39288262
A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application., PMID:39229258
Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity., PMID:39043643
NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody., PMID:38943249
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E., PMID:35596615
Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing., PMID:35184420
Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients., PMID:34284214
All-Atom Simulations Reveal a Key Interaction Network in the HLA-E/NKG2A/CD94 Immune Complex Fine-Tuned by the Nonameric Peptide., PMID:34196180
Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer., PMID:33501768
Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies., PMID:33415981
Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis., PMID:33108906
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment., PMID:32409305
Monalizumab: inhibiting the novel immune checkpoint NKG2A., PMID:31623687
Echinococcus multilocularis inoculation induces NK cell functional decrease through high expression of NKG2A in C57BL/6 mice., PMID:31500589
Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease., PMID:31478993
Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study., PMID:31378695
Simian Immunodeficiency Virus Infection Modulates CD94+ (KLRD1+) NK Cells in Rhesus Macaques., PMID:31167916
Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment., PMID:30871626
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells., PMID:30860984
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia., PMID:30705677
Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities., PMID:27312286
Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans., PMID:26940026
Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., PMID:26453102
Overlap Chronic Placental Inflammation Is Associated with a Unique Gene Expression Pattern., PMID:26207633
Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression., PMID:23199330
IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion., PMID:20956026
Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy., PMID:20580616
Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade., PMID:20139023
Killer cell immunoglobulin-like receptor expression induction on neonatal CD8(+) T cells in vitro and following congenital infection with Trypanosoma cruzi., PMID:19922420
Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis., PMID:18700876
The role of invariant NKT cells in pre-eclampsia., PMID:18573130
Uncommon endocytic and trafficking pathway of the natural killer cell CD94/NKG2A inhibitory receptor., PMID:18363778
Implication for the CD94/NKG2A-Qa-1 system in the generation and function of ocular-induced splenic CD8+ regulatory T cells., PMID:18359787
NKG2A inhibits TH2 cell effector function in vitro., PMID:17927829
Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit., PMID:17681668
Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion., PMID:17521371
Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway., PMID:17509909
Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer., PMID:16621903
Impaired NK cell cytotoxicity by high level of interferon-gamma in concanavalin A-induced hepatitis., PMID:16391713
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts., PMID:16384928
Amelioration of acute graft-versus-host disease by NKG2A engagement on donor T cells., PMID:15997467
Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway., PMID:15978547
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104., PMID:15937142
Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys., PMID:15899917
Expression of MHC class I receptors confers functional intraclonal heterogeneity to a reactive expansion of gammadelta T cells., PMID:15864777
Molecular and functional characterization of NKG2D, NKp80, and NKG2C triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function during simian HIV infection., PMID:15843571
For research use only. Not for human or drug use.
